Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Current Liabilities (2016 - 2025)

Zevra Therapeutics' Total Current Liabilities history spans 11 years, with the latest figure at $39.3 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 15.3% year-over-year to $39.3 million; the TTM value through Dec 2025 reached $39.3 million, up 15.3%, while the annual FY2025 figure was $39.3 million, 15.3% up from the prior year.
  • Total Current Liabilities reached $39.3 million in Q4 2025 per ZVRA's latest filing, up from $26.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $73.7 million in Q4 2023 to a low of $2.9 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $21.4 million, with a median of $20.0 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: plummeted 94.78% in 2021, then soared 513.16% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $4.2 million in 2021, then surged by 184.23% to $12.0 million in 2022, then skyrocketed by 513.16% to $73.7 million in 2023, then crashed by 53.79% to $34.1 million in 2024, then rose by 15.3% to $39.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Total Current Liabilities are $39.3 million (Q4 2025), $26.1 million (Q3 2025), and $28.8 million (Q2 2025).